Trevi Therapeutics Inc (TRVI NASDAQ) stock market data APIs
$3.52
-0.26(-6.9%)
as of January 22, 2025
Trevi Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Prev. Close
3.78
Open
3.52
Volume
534 K
High
3.955
Low
3.4715
52 wk Range
1.34-4.68
Market Cap
338 M
Shares Outstanding
89 366 K
Revenue
0
EPS
-0.13
Beta
1.014
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Trevi Therapeutics Inc data using free add-ons & libraries
Get Trevi Therapeutics Inc Fundamental Data
Trevi Therapeutics Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -48 070 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-06
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Trevi Therapeutics Inc News
New
Presenting on the Emerging Growth Conference on February 22 Register Now
MIAMI, Feb. 21, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 50th Emerging Growth Conference on February 22, 2023. The Emer...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has o...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has o...
Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AVEO Pharmaceuticals (AVEO) is a stock that can certainly grab t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
